- Home
- MCI vs RGNX Comparison
MCI vs RGNX Comparison
Compare MCI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- RGNX
- Stock Information
- Founded
- MCI 1971
- RGNX 2008
- Country
- MCI United States
- RGNX United States
- Employees
- MCI N/A
- RGNX N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCI Finance
- RGNX Health Care
- Exchange
- MCI Nasdaq
- RGNX Nasdaq
- Market Cap
- MCI 400.8M
- RGNX 356.7M
- IPO Year
- MCI N/A
- RGNX 2015
- Fundamental
- Price
- MCI $23.25
- RGNX $7.27
- Analyst Decision
- MCI
- RGNX Buy
- Analyst Count
- MCI 0
- RGNX 12
- Target Price
- MCI N/A
- RGNX $33.36
- AVG Volume (30 Days)
- MCI 40.4K
- RGNX 698.7K
- Earning Date
- MCI 01-01-0001
- RGNX 02-28-2025
- Dividend Yield
- MCI 8.46%
- RGNX N/A
- EPS Growth
- MCI N/A
- RGNX N/A
- EPS
- MCI 1.82
- RGNX N/A
- Revenue
- MCI N/A
- RGNX $84,327,000.00
- Revenue This Year
- MCI N/A
- RGNX $2.23
- Revenue Next Year
- MCI N/A
- RGNX $250.77
- P/E Ratio
- MCI $9.88
- RGNX N/A
- Revenue Growth
- MCI N/A
- RGNX N/A
- 52 Week Low
- MCI $12.96
- RGNX $6.56
- 52 Week High
- MCI $19.24
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- MCI 62.89
- RGNX 41.90
- Support Level
- MCI $21.00
- RGNX $6.92
- Resistance Level
- MCI $21.33
- RGNX $7.79
- Average True Range (ATR)
- MCI 0.79
- RGNX 0.44
- MACD
- MCI 0.29
- RGNX -0.04
- Stochastic Oscillator
- MCI 57.11
- RGNX 19.40
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. These investments are typically made to small or middle market companies. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.